Ongoing research indicates that antagonizing the CD47-SIRPA interaction can alleviate clinical symptoms in arthritis, colitis, and Crohn’s disease, making the CD47-SIRPA axis a potential therapeutic target for these conditions [46–48]. This evidence concerns the gene SIRPA and Crohn disease.